atai Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced it has entered into a collaboration with Massachusetts General Hospital and its new initiative, the Center for Neuroscience of Psychedelics, to advance novel… Read More
atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it has acquired a majority stake in Recognify Life Sciences, an entity developing a treatment for Cognitive Impairment associated with Schizophrenia (CIAS). Recognify’s lead compound, “RL-007”,… Read More
atai Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, has announced the appointment of Greg Weaver as Chief Financial Officer (CFO) and Rolando Gutierrez-Esteinou as Chief Medical Officer (CMO). Read More
